Evidence map›Paper›PMID 41870427›Full record

ArticleJAMA network open2026

Knowledge, Attitudes, and Behaviors Toward Human Papillomavirus Vaccination Among Adults in Switzerland.

Kyra Zens, Nora Baer, Selim Nur, Silvana Renner, Phung Lang

Abstract read
In one paragraph

Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kyra ZensEpidemiology, Biostatistics and Prevention Institute, Department of Public and Global Health, Immunity and Vaccines Research Group, University of Zurich, Zurich, Switzerland.
Nora BaerEpidemiology, Biostatistics and Prevention Institute, Department of Public and Global Health, Immunity and Vaccines Research Group, University of Zurich, Zurich, Switzerland.
Selim NurMerck Sharp & Dohme AG, Lucerne, Switzerland.
Silvana RennerMerck Sharp & Dohme AG, Lucerne, Switzerland.
Phung LangEpidemiology, Biostatistics and Prevention Institute, Department of Public and Global Health, Immunity and Vaccines Research Group, University of Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Human papillomavirus (HPV) vaccination prevents several cancers and genital warts, yet adult uptake in Switzerland remains poorly characterized. In addition to demographic factors, understanding how individuals' knowledge, attitudes, and behaviors (KAB) are associated with vaccine uptake may support strategies to address coverage gaps. Objective: To estimate adult HPV vaccination uptake in Switzerland and evaluate how population-level KAB profiles are associated with vaccination uptake. Design, Setting, and Participants: This nationwide, cross-sectional, population-based survey of adults throughout Switzerland was conducted between September 2023 and September 2024. Adults aged 18 to 45 years were randomly selected from a national residential registry using disproportionate stratified sampling by age, gender, and region. Participants completed a questionnaire on HPV-related KAB, and corresponding HPV immunization data were verified from individuals' personal vaccination records. Exposure: Individual KAB responses regarding HPV disease and vaccination, assessed through standardized questionnaires. Main Outcomes and Measures: The primary outcome was documented receipt of 1 or more HPV vaccine dose according to vaccination records. Latent class analysis was used to define KAB profiles, and multivariable logistic regression used to assess associations with HPV vaccination. Results: Of 41 645 valid addresses, 3847 individuals (9.2%) submitted both a questionnaire and a vaccination record and were included in the analysis. Among 3847 participants (2433 women [weighted 49.1%]; 1997 individuals aged 18-26 years [weighted 26.1%]), 27.2% (95% CI, 25.9%-28.6%) had received 1 or more HPV vaccine dose, with uptake varying by age (58.6% [95% CI, 56.2%-60.9%] for those aged 18-26 years vs 16.1% [95% CI, 14.6%-17.8%] for those aged 27-45 years), gender (42.8% [95% CI, 40.6%-45.0%] of women vs 12.2% [95% CI, 10.8%-13.8%] of men), and region. Three KAB profiles were identified: cluster 1 (2280 participants [52.9%]) showed high HPV awareness and perceived importance, cluster 2 (1099 participants [30.9%]) showed moderate knowledge and low perceived risk, and cluster 3 (468 participants [16.2%]) showed high uncertainty. Vaccination uptake was 41.1% (95% CI, 40.9%-41.2%) in cluster 1, 13.6% (95% CI, 13.4%-13.7%) in cluster 2, and 8.1% (95% CI, 7.9%-8.2%) in cluster 3. Lack of practitioner recommendation was the most common barrier to vaccination across profiles. Conclusions and Relevance: In this cross-sectional study of Swiss adults, in addition to demographic factors, distinct KAB profiles were associated with HPV vaccine uptake. Tailored communication strategies that (1) reinforce practitioner engagement, (2) address risk perception and skepticism, and (3) improve informational outreach may help to address remaining coverage gaps.

Indexed as

Health Knowledge, Attitudes, PracticePapillomavirus InfectionsPapillomavirus VaccinesPatient Acceptance of Health CareVaccinationAdolescentAdultCross-Sectional StudiesFemaleHuman Papillomavirus VirusesHumansMaleMiddle AgedSurveys and QuestionnairesSwitzerlandYoung AdultPapillomavirus Vaccines

Identifiers

PMID41870427
PMCPMC13010212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.